Why the study?
Arrhythmia-induced cardiomyopathy is often underestimated because arrhythmia is frequently viewed as a result rather than a cause of cardiomyopathy, leading to treatment delays.
Answers are grounded in this paper and cite their sources.
Arrhythmia-induced cardiomyopathy is a reversible cause of heart failure that requires early recognition and effective arrhythmia suppression to recover ventricular function.
Arrhythmia is one of the significant reversible causes in patients with heart disease and left ventricular dysfunction. Tachycardia, atrial fibrillation, and premature ventricular contractions have indeed been related to arrhythmia-induced cardiomyopathy (CM), a reversible dilated CM. Effective arrhythmia suppression will entirely or partially recover ventricular function, lowering morbidity and mortality. However, the importance of arrhythmia-induced CM (ARiCM) is often underestimated in clinical practice because arrhythmia is often seen as a result rather than a cause of CM, leading in treatment delays and failure to increase the quality of life and better clinical outcomes. This article review aims to summarize the pathomechanisms, and a general approach to the management of ARiCM and its long-term outcomes. ARiCM can cause a variety of clinical signs, ranging from asymptomatic to severe heart failure symptoms. Electrocardiogram, 24 h Holter monitoring, echocardiography, and cardiac magnetic resonance are all recommended for diagnosis. More research is required to better understand the pathogenesis of ARiCM and to differentiate treatment alternatives to choose the ideal ARiCM management approach.
No takes yet. Share an insight, caveat, or question.
Purwowiyoto et al. (2022) conducted a review in Arrhythmia-induced Cardiomyopathy. Arrhythmia suppression (Antiarrhythmic drugs or Radiofrequency ablation) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: